Drug Discovery AI Talk

00:22:28

#76. AI's Phase III Moment

Drug Discovery AI Talk ·

2026/10/02

On September 10, 2026, Insilico Medicine dosed the first patient in the Phase III GENESIS-IPF-3 trial of rentosertib (ISM001-055) for idiopathic pulmonary fibrosis - the first drug with both an AI-discovered target and an AI-designed molecule to reach Phase III. We break down the TNIK story, the Phase IIa data published in Nature Medicine, the provocative aging-clock signals in Nature Biotechnology, and what this milestone really proves - and doesn't - about AI drug discovery. Produced by Dr

en-us

00:20:37

#75. The AI Patent Landscape 2026

Drug Discovery AI Talk ·

2026/09/25

In this episode, we examine how AI-native biotechnology companies are reshaping drug discovery through the lens of their intellectual-property portfolios. The evidence suggests that these firms are becoming significantly more productive at generating patentable molecules, yet they have not demonstrated the same advantage in discovering entirely new biological targets. Companies such as Insilico Medicine and Genesis show clear strengths in chemical optimization and development speed, while insitro

en-us

00:20:32

#74. Is Drug Discovery AI Safe?

Drug Discovery AI Talk ·

2026/09/18

In this podcast, we study how integrating agentic AI into autonomous wet labs promises rapid therapeutic innovation, while connecting autonomous models directly to physical lab instruments creates critical security risks. These range from immediate hazards—such as cyber-physical vulnerabilities, sequence-screening evasion, and flawed objective optimization—to systemic risks from unaligned superintelligence and uncontrolled biological synthesis. Mitigating these threats requires a capability-based

en-us

00:18:51

#73. The Triumph of Daraxonrasib

Drug Discovery AI Talk ·

2026/09/11

For decades, KRAS stood as oncology’s archetypal “undruggable” target—a powerful cancer driver with no obvious pocket for conventional medicines to grasp. This episode explores how molecular-glue drugs such as daraxonrasib overturn that assumption by recruiting cyclophilin A to form a synthetic complex around active RAS, physically blocking its growth signals. From the structural ingenuity behind this molecular trap to emerging clinical promise in pancreatic and other KRAS-driven cancers, the

en-us

00:23:49

#72. 2026 Emerging Trends

Drug Discovery AI Talk ·

2026/09/04

In this podcast, we show a pivotal shift in 2026 for AI drug discovery toward integrated, AI-native R&D systems that move beyond simple algorithmic tasks to form closed-loop learning environments. In this new phase, the industry focuses on converting physical experiments into causal data to overcome information bottlenecks that mere model scaling cannot solve. Leading experts emphasize that generative abundance is creating a new challenge, making it more difficult to select the right candidate

en-us

00:24:20

#71. Magic Wands

Drug Discovery AI Talk ·

2026/08/28

In this episode, we critically examine whether AI drug discovery is solving the hardest problems in medicine—or simply making the easier ones faster. At the center of the discussion is Daphne Koller’s argument that the industry has invested heavily in computational molecular design while giving too little attention to the deeper challenge of understanding human disease biology. If the primary bottleneck is identifying the causal mechanisms that truly improve patient outcomes, then better molecule

en-us

00:22:47

#70. Beyond AlphaFold

Drug Discovery AI Talk ·

2026/08/24

In this episode, we venture beyond protein structure prediction into the messy, stochastic reality of modeling the virtual cell. We examine why biology still lacks an AlphaFold-like solution for predicting the behavior of entire cells and explore challenges spanning molecular interactions, cell-state transitions, perturbation responses, and clinical translation. Because cellular behavior is dynamic, context-dependent, and shaped by biological history, it cannot be captured simply by scaling

en-us

00:22:36

#69. CollaboFest

Drug Discovery AI Talk ·

2026/08/07

What if we could turn a spark of biological insight into a real-world, life-saving treatment? That is the core mission of CollaboFest, an innovative initiative designed to break down the slow, traditional bottlenecks of drug discovery. Organized by the University of Alabama at Birmingham's Systems Pharmacology AI Research Center (SPARC), alongside Southern Research, this unique program unites multidisciplinary teams from across the region. Together, these experts bridge the crucial gap between

en-us

00:22:23

#68. Molecular Glues in Therapy

Drug Discovery AI Talk ·

2026/07/31

In this episode, we explore the rapid evolution of molecular glues, a breakthrough in targeted protein degradation that stabilizes protein interactions to treat previously incurable diseases. Historically discovered by chance, this field is moving toward a systematic design approach by integrating artificial intelligence, functional genomics, and biased chemical libraries. Current research emphasizes using machine learning to predict complex protein interfaces and utilizing covalent bonding to

en-us

00:20:41

#67. Does Size Matter?

Drug Discovery AI Talk ·

2026/07/24

In this episode, we examine whether increasing the size and depth of neural networks truly enhances molecular property prediction compared to traditional machine learning. A recent study reveals that classical models using chemical fingerprints often outperform or match deep learning architectures, particularly when dealing with limited datasets or local structural variations. While foundation models and graph neural networks show promise when there is a significant difference between training and

en-us

00:26:02

#66. Quantitative Systems Pharmacology

Drug Discovery AI Talk ·

2026/07/17

In this episode, we explore the evolving role of Quantitative Systems Pharmacology (QSP) in drug development, particularly as a mechanistic alternative to traditional animal testing. It details how mathematical modeling can integrate human-relevant data and biological pathways to better predict drug safety and efficacy before clinical trials. The sources highlight recent 2026 FDA draft guidances that establish a regulatory framework for using these models to select initial human doses. While the

en-us

00:20:04

#65. Orbiting around Big Pharma

Drug Discovery AI Talk ·

2026/07/10

In this episode, we explore Lilly TuneLab as a major signal of where AI drug discovery may be heading: toward powerful platform ecosystems that combine proprietary pharmaceutical data, advanced predictive models, federated learning, and large-scale compute. On the positive side, platforms like TuneLab could help biotech companies derisk drug assets earlier, improve safety and pharmacokinetic predictions, reduce wasted experiments, and give smaller teams access to capabilities once reserved for Big

en-us

00:20:46

#64. Foundation Models

Drug Discovery AI Talk ·

2026/07/03

In this episode, we explore the surge of foundation models (FMs) within pharmaceutical research, noting that over 200 such models were published by early 2025. Unlike traditional task-specific AI, these versatile algorithms are pre-trained on massive datasets to identify broad biological patterns before being refined for specialized functions. We detail how FMs are currently applied to transcriptomics, protein structures, and pathology imaging to enhance the speed and efficiency of drug discovery

en-us

00:21:01

#63. The Era of NAMs

Drug Discovery AI Talk ·

2026/06/26

This podcast explores the transformative shift toward New Approach Methodologies (NAMs), which utilize human-relevant experimental and computational systems to modernize drug discovery and biomedical research. Major federal initiatives from the NIH and FDA are establishing a robust infrastructure for these technologies, moving them from peripheral alternatives to central organizing principles in regulatory science. The sources highlight how AI-driven integration of in vitro assays, such as organoids

en-us

00:18:48

#62. Predicting Toxicity

Drug Discovery AI Talk ·

2026/06/19

In this episode, we investigate the significant evolution of AI-driven toxicity prediction, detailing how the field has shifted from simple statistical models to sophisticated deep learning and multimodal systems. It highlights a variety of computational tools, distinguishing between modern machine learning platforms like ProTox 3.0 and established regulatory-facing frameworks such as the OECD QSAR Toolbox. We emphasize that while these technologies accelerate drug discovery and chemical

en-us

00:21:45

#61. AI Era Evidence Flywheel

Drug Discovery AI Talk ·

2026/06/12

In this episode, Dr. Jake Chen provides his narrative review and advocates for a fundamental shift in pharmaceutical research, moving away from inefficient trial-and-error toward an AI-augmented scientific discipline. The text outlines 12 core principles to transform drug discovery into a mechanism-aware system that prioritizes causal target biology, early safety prediction, and patient-centered strategies. Instead of using artificial intelligence simply to increase speed, Chen argues that these

en-us

00:21:28

#60. Cracking the "Undruggable" Target

Drug Discovery AI Talk ·

2026/06/06

Welcome to today's episode, where we dive into a monumental breakthrough in oncology, i.e., cracking the "undruggable" KRAS mutation. For decades, pancreatic cancer has been notoriously lethal, with few treatment options. Enter daraxonrasib (RMC-6236), a revolutionary "molecular glue" that targets the active "ON" state of mutated RAS proteins. In the recent Phase 3 RASolute 302 trial, this targeted therapy nearly doubled overall survival for metastatic pancreatic cancer patients compared to standard

en-us

00:18:52

#59. Drug Discovery AI Teammates

Drug Discovery AI Talk ·

2026/05/29

AI isn't replacing scientists in the lab — it's joining the team. This episode unpacks "capability complementarity," the framework where human creativity and contextual judgment fuse with AI's speed and scale to crack problems neither could solve alone. We explore multi-agent systems delegating molecule design, literature review, and analysis; why the "black-box" problem makes human-in-the-loop oversight non-negotiable in regulated pharma; and how the 2026 FDA-EMA joint guidance now scrutinizes the

en-us

00:14:43

#58. Do We Need Mavericks?

Drug Discovery AI Talk ·

2026/05/22

In this episode, we explore the evolution of leadership within the field of AI-driven drug discovery, identifying key figures who are reshaping how medicines are developed. It categorizes these "mavericks" into distinct archetypes, ranging from industrialized data factory builders like Chris Gibson to biological systems reformers like Aviv Regev. The analysis highlights that while generative AI has mastered molecular design, the greater challenge remains overcoming biological uncertainty and

en-us

00:23:01

#57. Do You Turst your AI?

Drug Discovery AI Talk ·

2026/05/15

These sources present a framework for transitioning from vague notions of "trusting" artificial intelligence in drug discovery toward a more rigorous system of calibrated reliance. Both documents emphasize that AI reliability must be evaluated within a specific context of use, requiring a transition from retrospective performance claims to prospective, leakage-resistant validation. To manage the high risks of pharmaceutical research, the authors propose a six-layer trust stack that

en-us

All Episodes

Similar Podcasts

Expres Ráno

Expres FM

Kan Hourly News כאן רשת ב חדשות - מהדורת השעה

Mr. Mp3

City Cast Denver

City Cast

Sweden in Focus

The Local

Tulsa News Today | 2 Min News | The Daily News Now!

The Daily News Now!